EXC 001 / Pfizer, Ionis - LARVOL DELTA

Isis Pharmaceuticals' management presents at Bank of America Merrill Lynch 2012 health care conference (Transcript) (SeekingAlpha) - Isis is excited to have Pfizer’s development & commercial market behind EXC 001 to move that forward into Phase 3 clinical trial

Anticipated clinical development • Fibrosis

Rodman & Renshaw Global Investment Conference (Isis Pharmaceuticals, Inc) - Anticipated launch for scarring resulting from surgery no later than 2017

Anticipated launch • Fibrosis

Anti-CTGF Oligonucleotide Reduces Severity of Postsurgical Hypertrophic Scars in a Randomized, Double-Blind, Within-Subject, Placebo-Controlled Study. (PubMed, Plast Reconstr Surg) - "This study provided positive preliminary data that intradermal injection of EXC 001 produced a significant reduction in severity of postsurgical skin scars, as measured by physicians, subjects, and an expert panel. This study provided evidence that suppression of CTGF could be a viable strategy for hypertrophic scar reduction therapy and that further study of the antisense oligonucleotide EXC 001 was indicated."

Clinical • Journal • Biosimilar • Breast Cancer • Oncology • Solid Tumor

Pfizer pipeline- as of July 28, 2015 (Pfizer Press Release) - PF-06473871 (EXC 001) in dermal scarring discontinued from development since Apr 28 2015.

Discontinued • Fibrosis

Morgan Stanley Global Healthcare Conference (Isis Pharmaceuticals, Inc) - Anticipated initiation of P3 trials for scarring resulting from surgery in 2013

Anticipated new P3 trial • Fibrosis

Isis Pharmaceuticals: Needham Healthcare Conference (Isis Pharmaceuticals, Inc) - Anticipated filing for treatment of scars by 2018

Anticipated regulatory • Fibrosis

Lazard Capital Market Healthcare Conference (Isis Pharmaceuticals, Inc) - Anticipated launch for fibrosis by 2017

Anticipated launch